PubRank

Mian M K Shahzad

Author PubWeight™ 35.69‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med 2012 3.54
2 Regulation of tumor angiogenesis by EZH2. Cancer Cell 2010 3.10
3 Sustained small interfering RNA delivery by mesoporous silicon particles. Cancer Res 2010 2.80
4 Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. J Clin Invest 2010 2.04
5 Surgical stress promotes tumor growth in ovarian carcinoma. Clin Cancer Res 2009 1.73
6 Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models. Cancer Biol Ther 2010 1.71
7 Src activation by β-adrenoreceptors is a key switch for tumour metastasis. Nat Commun 2013 1.62
8 Therapeutic Targeting of ATP7B in Ovarian Carcinoma. Clin Cancer Res 2009 1.61
9 Glucose as a prognostic factor in ovarian carcinoma. Cancer 2009 1.59
10 EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma. J Natl Cancer Inst 2009 1.37
11 Targeted gene silencing using RGD-labeled chitosan nanoparticles. Clin Cancer Res 2010 1.34
12 EphA2 overexpression promotes ovarian cancer growth. Cancer Biol Ther 2008 1.13
13 Functional roles of Src and Fgr in ovarian carcinoma. Clin Cancer Res 2011 1.08
14 Biological roles of the Delta family Notch ligand Dll4 in tumor and endothelial cells in ovarian cancer. Cancer Res 2011 1.05
15 Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer. Mol Cancer Ther 2010 1.04
16 Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth. Clin Cancer Res 2008 1.04
17 Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma. Cancer Biol Ther 2009 1.04
18 Silencing survivin splice variant 2B leads to antitumor activity in taxane--resistant ovarian cancer. Clin Cancer Res 2011 1.03
19 Converging evidence for efficacy from parallel EphB4-targeted approaches in ovarian carcinoma. Mol Cancer Ther 2010 1.02
20 Dopamine blocks stress-mediated ovarian carcinoma growth. Clin Cancer Res 2011 1.00
21 EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma. Clin Cancer Res 2010 0.95
22 Targeting SRC in mucinous ovarian carcinoma. Clin Cancer Res 2011 0.93
23 Multidrug resistance gene (MDR-1) and risk of brain metastasis in epithelial ovarian, fallopian tube, and peritoneal cancer. Am J Clin Oncol 2011 0.90
24 Impact of cardiovascular comorbidity on ovarian cancer mortality. Cancer Epidemiol Biomarkers Prev 2013 0.86
25 Biologic effects of dopamine on tumor vasculature in ovarian carcinoma. Neoplasia 2013 0.82
26 Therapeutic Dilemma: Prognostic Factors and Outcome for Neuroendocrine Tumors of the Cervix. Int J Gynecol Cancer 2016 0.75